Medartis Holding AG (MED) fair value: what the stock is really worth
As of Oct 26, 2026: fair value (intrinsic value) of Medartis Holding AG stock CHF 12.10, price CHF 93.60, upside -87.1%, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 22, 2026.
How to read this chart
60‑month range CHF 45.05 – CHF 145.60 · fair‑value band CHF 6.40 – CHF 18.45 · the CHF 93.60 price screens above the CHF 12.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 22, 2026.
Follow Medartis Holding in your weekly email
Every Wednesday you see whether Medartis Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide.
Show moreShow less
The company's medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery.
It provides products for the hand, wrist, forearm, elbow, shoulder, and foot and ankle, as well as for upper and lower extremities, mandible, midface, orthognathic under the APTUS and MODUS names, as well as CMX services through web portal, and kerimedical products.
The company was incorporated in 1997 and is headquartered in Basel, Switzerland.
Stock analysis
Medartis Holding AG (MED) currently trades at CHF 93.60, while our model-based Fair Value estimate is CHF 12.10, 87.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of CHF 14.09 per share, and 0 of the 20 models we run sit above the CHF 93.60 price.
Bear case: the Asset-Based group reads lowest at CHF 1.85, and 20 of the 20 models stay below the price. Data coverage for this calculation is low.
Scenario range: CHF 6.40 (bear) to CHF 18.45 (bull), the price of CHF 93.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Medartis Holding AG reported revenue of CHF 269M in FY2025 versus CHF 160M in FY2021, a compound +13.9%/yr. Reported net income was CHF 8.3M in FY2025, compounding +5.1%/yr from FY2021.
Key figures
Market cap CHF 1.2B Small · P/E ratio 78.0 · P/S ratio 3.80 · EPS (TTM) CHF 1.20 · Net margin 4.9% · Return on equity 5.8% · Return on assets (EBIT) 1.6% · Operating margin 8.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 30% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −87%, MED screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (CHF 0.4300 to CHF 26.80). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
BearCHF 6.40Fair Value CHF 12.10BullCHF 18.45
Price CHF 93.60 · Upside -87.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (CHF 0.9863 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+19.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
Start year 2020 (pandemic). Over 10 years: +12.6% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+56.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+56.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.12.0% vs 4.1%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 1%
2025 sits 301% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+53.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+16.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +52.5% a year for the price and +15.4% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (2 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 328 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−87.1% · Bottom 25%
Profitability
Return on equity (12 months)5.8% · Above median
Return on assets1.5% · Below median
Net margin (12 months)4.9% · Below median
Operating margin (12 months)8.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)30.7% · Top 25%
Balance sheet
Debt / equity0.41× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)78.0× · Priciest 25%
P/B4.23× · Priciest 25%
P/S (12 months)3.80× · Pricier than median
Price / free cash flow124.9× · Priciest 25%
EV/EBITDA42.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 8
FUTURE (revenue growth)100· sector 32
PAST (return on equity)23· sector 16
HEALTH (low debt)80· sector 98
DIVIDEND (yield)0· sector 37
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medartis Holding AG Fair Value". https://www.fairvalue-calculator.com/stock/MED.SW
Frequently asked questions
Is Medartis Holding AG (MED) overvalued or undervalued?
As of Oct 22, 2026, our model estimates a fair value of CHF 12.10 versus a price of CHF 93.60, about −87% upside (overvalued).
What is the fair value of MED?
Our model-based fair value for Medartis Holding AG is CHF 12.10 (as of Oct 22, 2026), built from audited fundamentals. The current price: CHF 93.60.
What is the quality score of MED?
Medartis Holding AG has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medartis Holding AG (MED)?
Our model-based price target is the fair value of CHF 12.10 (as of Oct 22, 2026) from 20 valuation models. Cautious scenario CHF 6.40, optimistic scenario CHF 18.45. It is a calculation from audited fundamentals, not an analyst target.
What is the Medartis Holding AG stock forecast for 2026?
Our models put fair value at CHF 12.10, about −87% upside versus a price of CHF 93.60 (overvalued). Cautious scenario CHF 6.40, optimistic scenario CHF 18.45. The calculation is refreshed regularly with new filings.
What is the revenue of Medartis Holding AG (MED)?
Medartis Holding AG reported trailing-twelve-month revenue of about CHF 307M (latest available figure, as of Oct 22, 2026).
What growth is priced into Medartis Holding AG (MED)?
For today's price to be fair in a discounted-cash-flow model, Medartis Holding AG would have to grow free cash flow by +53.5 % per year for five years (discount rate 11.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.1 % per year. As of Oct 22, 2026.
What discount rate (WACC) does the fair value of MED use?
Our models discount Medartis Holding AG at 11.5 %: a base by market capitalisation (small), damped by beta 1.17, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medartis Holding AG that is +53.5 % per year a year over ten years, using the same discount rate (11.5 %) and the same formula as our fair value.
How much growth has Medartis Holding AG (MED) delivered so far?
Over the past 5 years revenue at Medartis Holding AG grew +16.1 % a year. The price currently implies +53.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medartis Holding AG (MED) growing?
The median revenue growth in the sector is +5.8 % a year. That is the yardstick for the growth priced into Medartis Holding AG (+53.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medartis Holding AG (MED)?
The free-cash-flow yield on the price is 0.80 %: that much free cash flow Medartis Holding AG produces per unit of market value. When it exceeds the discount rate of our models (11.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medartis Holding AG (MED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medartis Holding AG it is CHF 12.10 per share (as of Oct 22, 2026), against a price of CHF 93.60. It is the blended result of 20 valuation models (cash flow, earnings, asset, dividend).
Is Medartis Holding AG stock overvalued or undervalued in 2026?
As of Oct 22, 2026, MED trades above its calculated fair value: price CHF 93.60, fair value CHF 12.10, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MED?
No. The price is what the market pays today (CHF 93.60); the fair value is what the company's own numbers justify (CHF 12.10). For Medartis Holding AG the two are CHF 81.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medartis Holding AG worth?
The market values Medartis Holding AG at about CHF 1.2B (market capitalisation, as of Oct 22, 2026). Per share that is CHF 93.60; our models calculate a fair value of CHF 12.10 per share.
What do the bullish and bearish scenarios say about MED?
Our models span a range for Medartis Holding AG: cautious scenario CHF 6.40, base CHF 12.10, optimistic CHF 18.45 per share (as of Oct 22, 2026, price CHF 93.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MED?
Medartis Holding AG trades at a price-to-earnings ratio of 78.0 (as of Oct 22, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 12.10 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 191.0 (reported for FY2025: 139.5). Median P/E at fiscal year-end, 6 fiscal years (2018 to 2025), reported earnings, FY2025 ex one-offs: 211.9. Other multiples: P/B 4.2, P/S 3.8, EV/EBITDA 42.9.
How solid is the balance sheet of Medartis Holding AG (MED)?
Balance-sheet figures for Medartis Holding AG (as of Oct 22, 2026): return on equity 5.8%, debt of 0.41 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is MED from its 52-week high?
Medartis Holding AG trades at CHF 93.60, about 4% below its 52-week high of CHF 97.50 and 30% above the low of CHF 72.00 (as of Oct 26, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 12.10 is for.
Which stocks are comparable to Medartis Holding AG?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medartis Holding AG stock attractive at the current price?
The data as of Oct 22, 2026: price CHF 93.60, calculated fair value CHF 12.10 (−87%), Quality Score 50/100, from 20 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MED calculated?
We run Medartis Holding AG through 20 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 12.10, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.7 % above its aggregate fair value. Medartis Holding AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medartis Holding AG (MED)?
The closing price on Oct 26, 2026 was CHF 93.60. Our model-based fair value is CHF 12.10, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medartis Holding AG right now?
The price sits above even our optimistic bull case (CHF 18.45). The favourable scenario is already priced in. The model range is unusually wide (CHF 6.40 to CHF 18.45). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Medartis Holding AG (MED) come from?
Earnings per share at Medartis Holding AG grew −3.4 % a year from 2015 to 2025. Broken into its drivers: revenue per share +11.7 %, EBIT margin −15.4 %, tax rate −0.6 %, residual (interest, one-offs) +2.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Medartis Holding AG
How large is the market capitalisation of Medartis Holding AG (MED)?
The market capitalisation of Medartis Holding AG is CHF 1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medartis Holding AG (MED)?
The price-to-sales ratio of Medartis Holding AG is 3.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medartis Holding AG (MED)?
Earnings per share at Medartis Holding AG are CHF 1.20 (price ÷ EPS = P/E 78.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medartis Holding AG (MED)?
The net margin of Medartis Holding AG is 4.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medartis Holding AG (MED)?
The return on equity (ROE) of Medartis Holding AG is 5.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medartis Holding AG (MED)?
On an EBIT basis the return on assets of Medartis Holding AG is 1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medartis Holding AG (MED)?
The operating margin of Medartis Holding AG is 8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medartis Holding AG (MED)?
Revenue at Medartis Holding AG is growing +30.7% versus a year earlier (3y avg +13.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medartis Holding AG (MED)?
Earnings per share at Medartis Holding AG are growing +10.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medartis Holding AG (MED) carry?
The net debt of Medartis Holding AG is CHF 125M (fiscal year 2025, ≈ 13.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medartis Holding AG in the live analysis
One click puts Medartis Holding AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 22, 2026